Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Kathleen M. Dungan MD, MPH Advisory Board

Deborah J. Wexler MD, MSc Associate Editor

See All Experts

featured

Published in Diabetes and

Journal Scan / Consensus and Guidelines · May 04, 2021

AHA Statement on Obesity and CVD

Circulation

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Robert Kushner MD, MS, DABOM

Ildiko Lingvay MD, MPH, MSCS

Circulation

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Circulation 2021 Apr 22;[EPub Ahead of Print], TM Powell-Wiley, P Poirier, LE Burke, JP Després, P Gordon-Larsen, CJ Lavie, SA Lear, CE Ndumele, IJ Neeland, P Sanders, MP St-Onge, American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

AHA Statement on Obesity and CVD

Additional Info

Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Further Reading

Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity

Prevalence of Metabolic Syndrome Among Children and Adolescents With Obesity

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes — 2025

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Weight Changes After Treatment With Semaglutide in Individuals With MASLD/MASH With or Without Type 2 Diabetes

Potential Off-Label Indication of Metformin for Ischaemic Stroke

GLP-1 Agonists Combined With GIP and/or GCG Agonists vs GLP-1 Agonists Alone for Weight Loss in Adults With Obesity Without Type 2 Diabetes

Recently Updated